[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medical University of Vienna\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":683},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,142,0,25,[9,42,70,94,120,150,170,198,231,256,287,312,333,360,386,409,435,454,476,499,535,559,584,611,646],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100543556","association-of-anti-factor-xa-activity-with-venous-thromboembolism-in-critically-ill-patients-100543556",false,"NCT06357403","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients","Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients: a Prospective Multicentre Cohort Study","AntiXa-ICU","Inclusion Criteria:\n\n* Age over 18 years at the time of intensive care unit admission\n* Admission to a participating intensive care unit within the last 24 hours\n* Expected discharge is later than 48 hours after enrolment\n\nExclusion Criteria:\n\n* Therapeutic anticoagulation, defined as enoxaparin dose of at least 100 IE\u002Fkg when given twice daily or of at least 150 IE\u002Fkg when given once daily\n* Extracorporeal membrane oxygenation in place or planned within 48 hours of study enrolment\n* Planned regular administration of vitamin K antagonists, unfractionated heparin, low molecular weight heparin other than enoxaparin, thrombin inhibitors or factor X inhibitors within the observation period\n* Estimated life expectancy below 48 hours or comfort terminal care order in place\n* Previously diagnosed heparin-induced thrombocytopenia\n* Pre-operative admission for elective surgery\n* Previous enrolment in the study","ALL","18 Years",{"count":21,"type":22},1300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to analyse the association between anti-factor Xa activity (antiXa) and the occurence of venous thromboembolism (VTE; either deep vein thrombosis and\u002For pulmonary embolism) in critically ill patients who are admitted to an intensive care unit. The main questions it aims to answer are:\n\n* What is the association between antiXa and VTE?\n* What is the association between antiXa and symptomatic, respectively incidental, VTE?\n* How is pharmacological anticoagulation with enoxaparin related to measured antiXa?\n* What is the association between antiXa and bleeding complications.\n* What is the incidence of venous thromboembolism in patients treated at an intensive care unit?\n* How is the occurence of VTE related to patient-centred outcomes such as mortality, quality of life, length of stay and days outside of the intensive care unit\u002Fhospital.",[26,27,28],"Thrombosis","Pulmonary Embolism","Enoxaparin","RECRUITING","2026-06-18",{"date":32,"type":33},"2026-06-23","ACTUAL",{"date":35,"type":33},"2024-05-04",{"date":37,"type":22},"2027-08",{"name":39,"class":40},"Medical University of Vienna","OTHER",3,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100642829","comparison-of-tunneled-cuffed-dialysis-catheters-versus-arteriovenous-fistulae-in-elderly-or-multimorbid-patients-100642829","NCT07649083","Comparison of Tunneled Cuffed Dialysis Catheters Versus Arteriovenous Fistulae in Elderly or Multimorbid Patients","Inclusion Criteria:\n\n* Aged ≥60 years or \\\u003C60 years with a CCI Score \\>6\n* Patients with CKD G5 A1-3 with indication for hemodialysis\n* Stable clinical condition\n* Eligibility for both arteriovenous fistula on the upper extremities and TCC\n* Availability for follow-up\n* Written informed consent\n\nExclusion Criteria:\n\n* Uncontrolled infection and\u002For CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl) at screening\n* Poor overall health or malignancy not in remission at screening\n* Major surgery within 12 weeks before screening\n* Pre-existent vascular access\n* Patient not eligible for any one of the vascular access options\n* Endovascular arteriovenous fistula","99 Years",{"count":50,"type":22},220,"INTERVENTIONAL",[53],"NA","Patients are randomly assigned to a study group. Depending on the study group, either an arteriovenous fistula or tunneled cuffed catheter (TCC) will be implanted, followed by continuous evaluation of the patients during the first year after initiating the vascular access. The evaluation includes statistical evaluation of all events, including loss of access, thrombosis, infection, loss of patency, increase in co-morbidities, e.g. congestive heart failure as well as quality of life. The implantation of the TCC is a standard procedure and it will be used only in accordance with the approved instructions of use on subjects who have signed an informed consent form. The surgery is a standard operation and it will be performed by specialized surgeons on subjects who have signed an informed consent form (No grafts will be used; implantation of a standard TCC, used at the Department of Nephrology). Both, an arteriovenous fistula or a TCC, will be used for routine chronic haemodialysis",[56,57,58,59,60],"End Stage Renal Failure, Hemodialysis","Vascular Access","Fistulas Arteriovenous","Haemodialysis Complication","Haemodialysis Patients","NOT_YET_RECRUITING","2026-06-11",{"date":64,"type":33},"2026-06-16",{"date":66,"type":22},"2026-08-01",{"date":68,"type":22},"2030-12-31",{"name":39,"class":40},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":51,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100641241","impact-of-a-tunneled-hemodialysis-catheter-with-endexo-technology-on-catheter-dysfunction-compared-with-historical-catheter-dysfunction-data-in-standard-catheters-100641241","NCT07655544","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters","Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters (Silicone or Polyurethane): A Pilot Study","Inclusion Criteria:\n\n* Adult patients aged greater than 18 years\n* Written informed consent\n* Requirement for hemodialysis using a tunneled dialysis catheter\n\nExclusion Criteria:\n\n* Children aged less than 18 years\n* Uncontrolled infection; defined as positive blood culture in the past seven days before catheter insertion and\u002F or elevated C-reactive protein \\[CRP \\>5 mg\u002Fdl (normal \\\u003C0.5 mg\u002Fdl)\\] at screening",{"count":78,"type":22},50,[53],"There is evidence that central venous catheters made of the permanent and non-eluting integral polymer Endexo® are more resistant to intraluminal thrombosis. This has a direct reducing effect on catheter malfunctions. Indirectly, due to reduced handling of the dysfunctional catheter, this may lead to a diminished rate of catheter related infections. Since catheter malfunctions and infections represent leading complications in a dialysis population, dialysis catheters produced with Endexo® technology have the potential to have beneficial clinical effects. In addition to improving patient outcomes, this could also reduce overall costs. In this pilot study the tunneled hemodialysis catheter BioFlo Duramax with Endexo® technology (Merit Medical, Utah, USA) will be compared with historical catheter dysfunction rates in standard tunneled dialysis catheters (silicone or polyurethane) in chronic dialysis population.",[82,59,57,83,84,85,86,87],"Haemodialysis","Vascular Access Complication","ESRD (End Stage Renal Disease)","Dialysis Access Dysfunction","Dialysis Catheter","Dialysis Catheter Infections",{"date":30,"type":33},{"date":66,"type":22},{"date":91,"type":22},"2027-12-31",{"name":39,"class":40},1,{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100643650","intensive-care-outcome-prediction-using-admission-carbohydrate-deficient-transferrin-100643650","NCT07632716","Intensive Care Outcome Prediction Using Admission Carbohydrate-deficient Transferrin","IMPACT - Intensive Care Outcome Prediction Using Admission Carbohydrate-deficient Transferrin A Prospective Single-center Cohort Study","IMPACT","Inclusion Criteria:\n\n* all patients ≥ 18 admitted to the Department of Emergency Medicine and subsequently transferred to an in-house intensive care unit (ICU)\n\nExclusion Criteria:\n\n* Patients transferred to other hospital departments prior to completion of intensive care\n* Patients admitted directly to the ICU without passing the ED\n* Patients admitted to intermediate care units\n* Patients with pre-existing or newly diagnosed hepatic cirrhosis\n* Patients with known or obvious pregnancy will be excluded.\n* Patients with no vascular access",{"count":103,"type":22},800,"The goal of this observational study is to learn whether hazardous alcohol consumption, measured objectively by carbohydrate-deficient transferrin (CDT) levels at intensive care unit (ICU) admission, is associated with worse outcomes in critically ill patients. The main question it aims to answer is:\n\nDo elevated CDT levels at ICU admission predict increased short-term mortality and adverse clinical outcomes in adult non-traumatic ICU patients? Participants admitted to the intensive care unit via the emergency department will have CDT levels measured as part of the study. Researchers will then collect and analyze clinical data, including mortality, duration of mechanical ventilation, delirium, ICU length of stay, renal replacement therapy, and ICU readmission rates, during hospitalization and follow-up.",[106,107,108],"Intensive Care (ICU)","Critical Illness","Alcohol Misuse",[110,107,111],"Alcohol-Related Disorders","Intensive Care Units","2026-06-02",{"date":114,"type":33},"2026-06-08",{"date":116,"type":22},"2026-06",{"date":118,"type":22},"2028-07",{"name":39,"class":40},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":129,"targetDuration":131,"studyType":23,"phases":4,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":93},"100643020","balance-ards-deconvolution-by-bronchoalveolar-lavage-multiomics-and-radiomics-100643020","NCT07633366","BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics","Check the BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics Profiling and Radiomics","BALance","Inclusion Criteria:\n\n* male and female\n* aged 18 years or over\n* signed consent form\n* depending on the study group: Confirmed ARDS according to the Berlin criteria (see below, Groups B and D) Confirmed severe CAP requiring mechanical ventilation and intensive care (see below, Groups B and C) Ventilated patients without signs of ARDS (see below, Group E)\n\nExclusion Criteria:\n\n\\- under 18 years of age",true,{"count":130,"type":22},130,"4 Years","Acute respiratory distress syndrome (ARDS) is a major contributor to ICU mortality and is characterised by hypoxaemia and pulmonary oedema. Pathomechanisms include barrier breakdown, immunopathology, haemostatic derailment and dysbiosis; however, the actual sequence of events and how they cumulatively lead to lung failure remains unclear. Although ARDS is frequently triggered by pneumonia, it can also occur as a result of trauma, aspiration or non-pulmonary causes. Importantly, ARDS is highly heterogeneous; growing evidence points to aetiology-specific pathomechanisms - a circumstance that explains why attempts to develop specific drugs or timely diagnostic markers have so far failed.\n\nA comprehensive analysis of key microenvironmental and haemostasis-related parameters of the lung, combined with multidimensional quantitative image features derived from chest CT scans (radiomics), will enable us to i) identify ARDS phenotypes with different biological characteristics and ii) generate new hypotheses regarding aetiology- or subgroup-specific mechanisms, molecular markers and therapeutic options.\n\nOur approach is based on ICU management of our patients guided by bronchoalveolar lavage fluid (BALF). Together with previously sampled cases and new samples collected as part of this study, our cohort will consist of patients with i) COVID-19-associated ARDS, ii) ARDS associated with other viral pneumonia, iii) ARDS associated with bacterial pneumonia, and iv) ARDS of non-pulmonary origin. Bacterial and fungal co-infections and superinfections are recorded in all patients and taken into account in the stratification. Patients with pneumonia without ARDS, as well as ventilated patients without underlying lung disease, serve as controls. To characterise the microbial lung microenvironment, the investigators combine data from routine microbiological diagnostics with microbiome sequencing and metabolomics. In addition, the investigators conduct comprehensive and longitudinal immune and haemostatic profiling by regularly analysing immune cells, cytokines and parameters of immune thrombosis in BALF and blood. Multi-omics integration then identifies phenotypic subgroups by merging all multimodal datasets - including radiomics. Selected samples from identified clusters are then further characterised using single-cell sequencing to uncover specific features\u002Fmarkers and pathomechanisms of the respective ARDS subtypes.\n\nAlthough it is clear that the pathogenesis of ARDS is multifactorial, comprehensive studies that integrate all relevant parameters are rare. Radiomics is increasingly recognised as a powerful tool for capturing the clinical status of ARDS in detail; however, to date, this imaging data has not been systematically linked to other omics readouts. The investigators aim to bridging this gap by conducting a thorough investigation across various ARDS aetiologies in the present study, incorporating all identifiable key factors.\n\nOur interdisciplinary team comprises basic immunologists, infectious disease and computational biologists, as well as clinicians with expertise in ARDS, infectious diseases, immunothrombosis and radiology.",[134],"ARDS (Acute Respiratory Distress Syndrome)",[136,137,138,139,140,141,142,143],"ARDS","BALF","COVID-19","Influenza","Co-Infection","Pneumonia","viral","bacterial",{"date":114,"type":33},{"date":146,"type":22},"2026-06-01",{"date":148,"type":22},"2030-06-01",{"name":39,"class":40},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":51,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":93},"100638377","personalized-targeted-glioblastoma-therapies-by-ex-vivo-drug-screening-advanced-brain-tumor-therapy-clinical-trial-in-patients-scheduled-for-short-course-radiation-100638377","NCT07627334","Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial In Patients Scheduled for shOrt Course radiatioN","ATTRACTION","Inclusion Criteria:\n\n* ECOG performance status 0-2\n* Newly diagnosed glioblastoma, IDH-wildtype - according to the 2021 WHO classification of Tumors of the Central Nervous System\n* Unmethylated MGMT promotor per local assessment\n* Successful PDC establishment and PDCs available for drug screening - based on inclusion in one of the following studies: (EK Nrs. (a) Medical University of Graz: 32-650 ex 19\u002F20; (b) Medical University of Vienna: 1407\u002F2021; (c) Karl Landsteiner University of Health Sciences: GS1-EK-4\u002F823-2022; (d) Kepler University Hospital Linz: 1323\u002F2022; (e) Medical University of Innsbruck 1003\u002F2023) and follow-up ethics covering the establishment of an Austrian GlioBank (EK Nrs. (a) Medical University of Graz: 36-253 ex 23\u002F24; (b) Medical University of Vienna: 2186\u002F2023; (c) Karl Landsteiner University of Health Sciences: GS3-EK-1\u002F211-2024; (d) Kepler University Hospital Linz: 1002\u002F2024; (e) Medical University of Innsbruck 1095\u002F2024)\n* Scheduled short-course radiotherapy with or without concomitant temozolomide\n* Written informed consent\n* No exclusion criteria\n\nExclusion Criteria:\n\n* Current participation in another therapeutic clinical trial.\n* Patients with a concurrent malignancy or malignancy within five years of study enrolment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma or stage I uterine cancer within the last 3 years.\n* Pregnant or lactating women.\n* Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection are eligible. Patients positive for anti-HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n* Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥350 cells\u002Fmm3, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended.\n* Participants who are unable or unwilling to comply with the requirements of the protocol as assessed by the investigator.",{"count":158,"type":22},30,[53],"Patients will receive in addition to standard histology analysis also the PDC- based drug screening.",[162],"Glioblastoma (GBM)","2026-05-31",{"date":165,"type":33},"2026-06-04",{"date":146,"type":22},{"date":168,"type":22},"2029-01-01",{"name":39,"class":40},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":93},"100638835","optimize-55---optimizing-impella-55-outcomes-through-advanced-data-science-100638835","NCT07619144","OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science","Clinical Outcomes and Adverse Events Associated With Microaxial Flow Pump Support: An Explorative Retrospective Study","OPTIMIZE","Inclusion Criteria:\n\n* Adult patients who were treated for cardiogenic shock and supported with an Impella 5.5 micro-axial flow pump\n* Only patients with available high-resolution pump data (downloaded from the clinical console) and ICU digital health record datasets\n\nExclusion Criteria:\n\n* Patients supported with an Impella 5.5 for indications other than cardiogenic shock (e.g., protected PCI or CABG)\n* Patients younger than 18 years\n* Patients with incomplete data, procedural records, or demographic information",{"count":179,"type":22},100,"The main goal of this observational, study is to develop a clinical decision support tool utilizing Impella 5.5 pump parameters to predict native heart recovery and prevent adverse events, by leveraging data science and real-world clinical data of cardiogenic shock patients.\n\nTherefore, secondary objectives are essential to consolidating a retrospective longitudinal analysis of Impella 5.5 pump data alongside ICU digital health record datasets to:\n\n1. Validate the Impella 5.5 placement signal by comparing it with ICU arterial line waveforms.\n2. Integrate pump data with ICU clinical data to identify patterns associated with therapy outcomes, including native heart recovery, heart replacement therapy, and mortality while on device support.\n3. Define clinical scenarios linked to hemolysis, HRAEs, and arrhythmias and develop predictive models to mitigate their occurrence.",[182,183,184],"Cardiogenic Shock","Mechanical Circulatory Support","Cardiogenic Shock Post Myocardial Infarction",[186,187,188,189,190],"cardiogenic shock","mechanical circulatory support","Impella 5.5","micro-axial flow pump","data science","2026-05-27",{"date":146,"type":33},{"date":194,"type":33},"2026-05-08",{"date":196,"type":22},"2029-05-30",{"name":39,"class":40},{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":18,"minAge":205,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":51,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":93},"100637399","unilateral-ventilation-on-cardiopulmonary-bypass-during-cardiac-surgery-100637399","NCT07612709","Unilateral Ventilation on Cardiopulmonary Bypass During Cardiac Surgery","Unilateral Ventilation on Cardiopulmonary Bypass During Cardiac Surgery in Patients at Increased Risk for Severe Postoperative Pulmonary Complications","Inclusion Criteria:\n\n* Patients at increased risk for postoperative pulmonary complications\n* Major elective cardiac surgery\n* Prolonged duration of cardiopulmonary bypass\n* Patients older than 65 years of age\n* Informed consent\n\nExclusion Criteria:\n\n* Emergency\n* Urgent procedures\n* Patients with implanted pacemakers\n* Patients with internal cardioverter\u002Fdefibrillators\n* Decompensated cardiac disease\n* Pulmonary disease\n* Recent pneumonia\n* Need for temporary perioperative mechanical support\n* Patients not willing to participate\n* Treatment with inhaled nitric oxide","65 Years",{"count":207,"type":22},45,[53],"This study investigates if single lung ventilation on cardiopulmonary bypass can mitigate postoperative lung water accumulation determined by lung ultrasound in the ventilated lung as compared to the non-ventilated lung in patients at high-risk for developing severe pulmonary complications after cardiac surgery.",[211,212,213,214,215,216,217,218,219,220,221,222],"Lung Protective Ventilation","Cardiopulmonary Bypass","High-risk Cardiac Patients","Lung Ultrasound","Lung Water Assessment","Pulmonary Complications in Surgical Patients","Single-lung Ventilation","Chest X-ray for Clinical Evaluation","Electrical Impedance Tomography (EIT)","Lung Compliance","Oxygenation Indices","Biomarkers of Vascular Endothelial Injury","2026-05-24",{"date":225,"type":33},"2026-05-29",{"date":227,"type":22},"2026-10-01",{"date":229,"type":22},"2029-07-31",{"name":39,"class":40},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":239,"targetDuration":241,"studyType":23,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":255},"100640745","austrian-pbc-registry-100640745","NCT07598669","Austrian PBC Registry","Characterisation of Patients With Primary Biliary Cholangitis in Austria - A Prospective Registry and Biobank","PBC-AUT","Inclusion Criteria:\n\n* Age \\>18 years\n* Confirmed diagnosis of primary biliary cholangitis (at least two of the following three criteria must be fulfilled: persistent elevation of alkaline phosphatase above the upper limit of normal for at least 6 months; presence of antimitochondrial antibodies or PBC-specific antinuclear antibodies; characteristic histopathology)\n* Written informed consent for participation in the registry\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent",{"count":240,"type":22},500,"10 Years","The goal of this registry is to better understand how primary biliary cholangitis develops over time, including the role of disease-related biomarkers, complications of the disease, and symptom burden. Patients with primary biliary cholangitis treated at participating centres in Austria will be invited to take part in this prospective registry. Participation in an associated biobank is optional. Clinical and laboratory data will be collected, and patients will be followed regularly through scheduled clinic visits. In addition, biological samples (serum, plasma, and, if available, liver tissue) may be collected and stored in the biobank for future research.",[244,245,246],"Primary Biliary Cholangitis","Liver Cirrhosis","Portal Hypertension","2026-05-16",{"date":249,"type":33},"2026-05-20",{"date":251,"type":33},"2026-03-18",{"date":253,"type":22},"2040-12",{"name":39,"class":40},11,{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":128,"sex":18,"minAge":19,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":51,"phases":266,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":4},"100637582","early-phase-1-pain-induced-by-m-cresol-as-preservative-100637582","NCT07600814","Pain Induced by m-Cresol as Preservative","Pain Induced by m-Cresol as Preservative - A Randomised Controlled Crossover-Trial in Healthy Volunteers","Inclusion criteria\n\n* Age between 18 and 70 years\n* Full legal capacity Exclusion criteria\n* Participant of another study, ongoing or within the last four weeks\n* Current medication intake (except hormonal contraception) or drug abuse\n* Female subjects: Positive pregnancy test or breastfeeding\n* Body temperature above 38°C, verified by infrared thermometer\n* Known allergic diseases, in particular asthmatic disorders and skin diseases\n* Sensory deficit, skin disease or hematoma of unknown origin in the examination of the test site","70 Years",{"count":265,"type":22},18,[267],"EARLY_PHASE1","Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth. However, clinical reports have suggested that these preservatives may cause local discomfort or pain at the injection site, which can negatively impact treatment adherence. While m-Cresol is widely used, its direct contribution to injection-site pain has not yet been investigated in a prospective clinical trial.\n\nThis study aims to investigate whether subcutaneous injection of m-Cresol at concentrations commonly used in clinical practice (0.1% and 0.25%) cause significantly more pain than a preservative-free control solution. In a randomized, double-blind crossover design, healthy volunteers will receive three separate injections in a belly fold. Participants will rate their pain every 5 seconds until it subsides. The findings will help determine if m-Cresol is a primary source of injection-site pain and could lead to the development of more comfortable drug formulations.",[270,271,272],"Pain","Acute Pain","Healthy Volunteer Study",[274,275,276,277,278,279],"m-Cresol","Preservative","Subcutaneous Injection","Human Pain Models","Experimental Pain Models","Nociception","2026-05-15",{"date":282,"type":33},"2026-05-22",{"date":284,"type":22},"2026-05-25",{"date":114,"type":22},{"name":39,"class":40},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":296,"conditions":297,"keywords":302,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":309,"leadSponsor":311,"locationsCount":93},"100640435","perception---super-early-neuroprognostication-in-ecpr-patients-100640435","NCT07584187","PERCEPTION - Super-Early Neuroprognostication in eCPR Patients","Super-Early Neuroprognostication in eCPR Patients: Feasibility of Automated Pupillometry and Cerebral Near-Infrared Spectroscopy - A Prospective Feasibility Study","PERCEPTION","Inclusion Criteria:\n\n* All patients ≥ 18 years evaluated for eCPR treatment at the Department of Emergency Medicine\n\nExclusion Criteria:\n\n* Return of spontaneous circulation before ECMO initiation.\n* Anatomical infeasibility for measurement, including but not limited to:\n* Severe facial trauma or deformity preventing the placement of the automated pupillometry device.\n* Scalp injuries, dressings, or conditions that interfere with the correct positioning of near-infrared spectroscopy (NIRS) sensors.\n* Pre-existing ocular conditions that preclude reliable pupillometry (e.g., enucleation, opaque cornea, or severe anisocoria unrelated to neurological status).",{"count":207,"type":22},"Background Extracorporeal cardiopulmonary resuscitation (eCPR) is a rescue therapy for a selected group of patients. Extracorporeal membrane oxygenation (ECMO) is initiated to bypass the cardiac system and bridge time to definitive treatment of the cardiac arrest (CA) origin. eCPR treatment is very time-critical and, if indicated, should be initiated as early as possible. Patient selection for this highly specific treatment is challenging and relies on numerous factors. In the following phase of intensive care treatment, neuroprognostication is performed. However, following current guidelines, this is only recommended 72hours after CA. Once ECMO is initiated, a complex intensive care treatment is expected, without a guarantee for full neurological recovery. There is a recognized clinical need for more precise selection criteria, alongside predictive values, to enable earlier, reliable neuroprognostication.\n\nAim This study aims to investigate whether super-early neuroprognostication before ECMO initiation is feasible. Super-early neuroprognostication will be performed using automated pupillometry and cerebral near-infrared spectroscopy (cNIRS) before ECMO initiation.\n\nMethods Patients evaluated for eCPR treatment at the Department of Emergency Medicine will be included in this study. By a study member not involved in clinical treatment, cNIRS and automated pupillometry will be performed before ECMO initiation and at predefined intervals: 10-20 minutes after ECMO Initiation, 1 hour (±15 minutes), 2 hours (±15 minutes), and 3 hours (±15 minutes). Follow-up measurements will be taken 24 hours (± 6 hours), 48 hours (± 6 hours), and 72 hours ± 6 hours after ECMO initiation. The secondary objective is to interpret the collected data regarding outcome parameters.",[298,299,300,301],"Resuscitation","Extra Corporeal Life Support","ECMO","Extracorporeal Cardiopulmonary Resuscitation",[303,300,304],"eCPR","CPR","2026-05-12",{"date":307,"type":33},"2026-05-14",{"date":305,"type":33},{"date":310,"type":22},"2028-10",{"name":39,"class":40},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":128,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":51,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":93},"100627676","multicpr-the-influence-of-resuscitation-on-history-recall-100627676","NCT07451730","MultiCPR: The Influence of Resuscitation on History Recall","MultiCPR4","Inclusion:\n\n* Healthy medical professionals trained in CPR (paramedics, prehospital emergency physicians, anesthesiologists, internal medicine doctors, nurses, midwifery students, pediatricians)\n* CPR Training in the last four years\n* Fit and rested.\n\nExclusion:\n\n\\- Pregnant probands",{"count":320,"type":22},38,[53],"In this randomized crossover trial, participants begin with chest compressions at a 30:2 ratio while a study team member provides ventilation. In Scenario A, participants perform two-person CPR and receive a prerecorded patient history after 30 seconds. In Scenario B, participants only listen to the patient's history without performing CPR or any concurrent task. To control for time-dependent memory decay, Scenario B includes a 3-minute delay before completing the questionnaire, matching the interval between information exposure and recall in Scenario A.\n\nAfter each scenario, participants complete the NASA-TLX workload assessment and a semi-open questionnaire on the patient's history. A modified Brown-Peterson task follows as a washout period: participants subtract 3 repeatedly from 309 for 1 minute, followed by 4 minutes of rest without phone use or conversation. Calculation performance is not analyzed.",[324],"Multitasking Behavior","2026-05-11",{"date":327,"type":33},"2026-05-13",{"date":329,"type":33},"2026-02-25",{"date":331,"type":22},"2026-11",{"name":39,"class":40},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":18,"minAge":205,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":51,"phases":343,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":93},"100629617","post-dilatation-in-balloon-expandable-tavi-prostheses-100629617","NCT07477002","Post-Dilatation in Balloon-Expandable TAVI Prostheses","Effects of Post-Dilatation on THV Expansion, Hemodynamics, Durability, and Outcomes in Balloon-Expandable TAVI Prostheses","DUOTAP","Inclusion Criteria:\n\n* Severe AS\n* AS treatment by transfemoral TAVI as determined by an interdisciplinary heart team board\n* Anatomical feasibility to receive a balloon-expandable THV\n* Age 65 years or older\n* Informed consent\n\nExclusion Criteria:\n\n* Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e., non compliant, perforated)\n* Bicuspid aortic valve anatomy\n* Valve-in-valve procedure\n* Severe calcification of the aortic annulus protruding into the left ventricular outflow tract and predisposing for annular rupture\n* Significant stenosis of the left main or proximal left anterior descending artery with substantial risk of hemodynamic instability during rapid ventricular pacing",{"count":342,"type":22},146,[53],"Asymmetrical and inadequate expansion of transcatheter heart valves (THVs) have been described as a key predictor of impaired valve hemodynamic performance predisposing patients for bioprosthetic valve dysfunction (BVD) and death. Post-dilatation using the original delivery system balloon at the identical filling volume after deployment of balloon-expandable THVs represents an invasive strategy to potentially optimize expansion and reduce asymmetry of balloon-expandable THVs. Currently, the efficacy and safety of routine post-dilatation has never been assessed in a randomized controlled fashion. The present randomized controlled DUOTAP trial aims to assess efficacy and safety of routine post-dilatation on THV expansion, hemodynamics, durability, and associated clinical outcomes in patients with severe aortic stenosis.",[346],"Aortic Valve Stenosis",[348,349,350,351,352],"Balloon-expandable TAVI prostheses","Fluoroscopic imaging","Computed tomography","Post-Dilatation","Double-Tap","2026-05-07",{"date":305,"type":33},{"date":356,"type":33},"2025-01-01",{"date":358,"type":22},"2031-05",{"name":39,"class":40},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":368,"maxAge":205,"enrollmentInfo":369,"targetDuration":4,"studyType":51,"phases":371,"briefSummary":372,"conditions":373,"keywords":375,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":93},"100633646","percutaneous-auricular-vagus-nerve-stimulation-with-conventional-rehabilitation-training-in-chronic-back-pain-patients-100633646","NCT07529392","Percutaneous Auricular Vagus Nerve Stimulation With Conventional Rehabilitation Training in Chronic Back Pain Patients","Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Combined With Conventional Rehabilitation Training to Improve Functional Outcome in Chronic Back Pain Patients (CURA): A Randomized Controlled Pilot Study","CURA","Inclusion Criteria:\n\n* Male or female aged ≥30 and ≤65 years\n* Indication: chronic myofascial\u002Fmusculoskeletal back pain\n* normal function of spinal nerves\n* Intractable pain for more than 6 months\n* Patient on oral pharmacotherapy ≤ WHO II with no adequate response or intolerant\n* Severity according to \"Leistungskategorie 2\" of BVAEB classification, which means Barthel Index 35-80, 6-minute walk test 300-480 m OR ergometry 50-80%\u002F0.75-1.25, ICF-Core-Sets grade 3\n* Average pain over the last 4 weeks according to painDETECT ≥ 4 and ≤ 9 at baseline\n* ODI 20-80 at baseline\n* Patient understands the therapy and procedures, agrees to its provisions, and gives written informed consent prior to any procedures\n\nExclusion Criteria:\n\n* Organic back pain (trauma, fracture, tumor, infection, severe degenerative spine, documented high-grade spinal stenosis, rheumatologic conditions)\n* Indication for back surgery\n* Radicular pain\n* Back surgery within the last 6 months\n* New analgesics 2 weeks before baseline (paracetamol, NSAIDs, Metamizol, etc.)\n* Opioid analgesic therapy \\> WHO II\n* Underwent other physical therapy modalities for back pain, also TENS, 2 weeks before baseline\n* History of vagus nerve stimulation or electrical auricular stimulation\n* History of vasovagal syncope\n* High BMI \\> 35 kg\u002Fm² (Obesity Class 2 or higher)\n* Hemophilia or strong anti-coagulation medication\n* Autonomic disorders\n* Advanced stage or poorly controlled diabetes mellitus type I or II\n* Poorly controlled high blood pressure\n* Major psychiatric comorbidity (at the discretion of the PI)\n* Other serious clinically relevant co-morbidity\n* History of arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies\n* Infection, eczema, or psoriasis at application site (ear and neck)\n* Numbed and desensitized skin at the application site (ear and neck)\n* Chronic drug or alcohol abuse within the last 6 months\n* Pregnant or nursing female patients\n* Active implantable device\n* Open pension request\n* Currently participating in another clinical trial or participated over the last 3 months\n* Relevant change in concomitant treatment or medication during the study","30 Years",{"count":370,"type":22},48,[53],"The therapeutic action of aVNS in pain treatment is based on the masking of pain by the electrical stimulation pulses, the activation of inhibiting pain control systems, and the release of neurotransmitters, such as endorphins. Pairing VNS stimulation with exercise and physiotherapy has yielded beneficial results in stroke patients as well as in smaller studies with back pain patients, already in short periods of time (2-4 weeks).\n\nThe current study is intended to evaluate the performance of percutaneous auricular Vagus Nerve Stimulation (pVNS) in combination with Standard-of-Care (SoC) in a 3-week in-patient rehabilitation setting, in patients with chronic musculoskeletal\u002Fmyofascial back pain. This will be a prospective, open, randomized, controlled pilot study to evaluate pVNS using the VIVO® wearable medical device for personalized pain treatment, in terms of feasibility, efficacy, and safety in combination with rehabilitation training. Patients will be randomized into one of the following treatment groups:\n\n* Group A: VIVO® (pVNS) + SoC (treatment group)\n* Group B: SoC (control\u002Fcomparator group) Patients will remain on treatment for 3 weeks. This is comparable to other studies performed earlier, which showed safe and effective use of pVNS in chronic pain patients. The additional follow-up period of 3 weeks (optional 3 months and 6 months) allows to evaluate sustainable effects of treatment and late time effects, as previously shown in other studies.\n\nPatients in the treatment group (VIVO® + SoC) will receive personalized aVNS therapy in combination with SoC. Personalization of VIVO® treatment is performed based on the individual perception level of the stimulation at the ear with regards to the stimulation amplitude (in Group A). Amplitude is adjusted (range 0-5 V) to reach a distinct but comfortable tingling sensation to reach activation of Aβ-fibers of the auricular vagus nerve but not Aδ-fibers producing a sensation of pain. Not only the Investigator is able to adjust the amplitude at the trial visit (via VIVO® Pen) but also the patient is able to adjust the amplitude according to his\u002Fher perception.\n\nPatients will be randomized in this pilot study to receive either aVNS with the VIVO® system in addition to SoC vs. SoC alone as comparator group. Estimates of performance endpoints will thus be contrasted between aVNS and an established treatment option in this indication and controlled for regression to the mean and other forms of sampling bias.\n\nAll concomitant medication and therapies will be thoroughly documented and taken into account in the final analysis.",[374],"Chronic Back Pain",[376,377],"Percutaneous Auricular Vagus Nerve Stimulation","Rehabilitation","2026-04-21",{"date":380,"type":33},"2026-04-24",{"date":382,"type":33},"2025-11-27",{"date":384,"type":22},"2027-03-15",{"name":39,"class":40},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":93},"100540835","video-interpreting-in-prehospital-emergency-medicine---feasibility-study-100540835","NCT06322004","Video-Interpreting in Prehospital Emergency Medicine - Feasibility Study","Inclusion Criteria:\n\n* adult patients, at least 18 years old\n* awake, responsive patients\n* language barrier (Albanian, Dari, Romanian, Turkish, Modern Standard Arabic, Arabic, Farsi, Russian, Hungarian, Bosnian-Croatian-Serbian, Kurdish (Kurmanci), Slovakian, Bulgarian, Polish, and Czech)\n\nExclusion Criteria:\n\n* unconscious patients\n* out-of-hospital cardiac arrest patients\n* delay of treatment or transportation due to e-interpreting\n* refusal of video-interpreting by the patient",{"count":78,"type":22},"50 responsive patients with language barriers will be included in this study. The prehospital emergency physician will start video-interpreting via a tablet. Feasibility, quality of communication, usability as well as changes in diagnosis and treatment will be gathered and analysed.",[395],"Communication Barriers",[397,398,399,400],"Communication barriers","Prehospital emergency medicine","Emergency medicine","Emergency physician","2026-04-15",{"date":403,"type":33},"2026-04-20",{"date":405,"type":33},"2023-02-06",{"date":407,"type":22},"2026-12-31",{"name":39,"class":40},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":128,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":51,"phases":418,"briefSummary":419,"conditions":420,"keywords":422,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":434},"100632692","intramuscular-injection-of-mashed-parathyroid-tissue-into-a-forearm-during-thyroid-surgery-to-prevent-permanent-postoperative-parathyroid-insufficiency-imipat-study-100632692","NCT07516990","Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoperative Parathyroid Insufficiency (IMIPAT Study)","Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoperative Parathyroid Insufficiency (IMIPAT Study) - a Prospective Multicentre Trial","IMIPAT","Inclusion Criteria:\n\n* signed informed consent\n* parathyroid autotransplantation in forearm performed during thyroid surgery\n* 18 years of age and above\n\nExclusion Criteria:\n\n* under 18 years of age\n* informed consent not signed\n* hyperparathyroidism\n* no parathyroid autotransplantation performed",{"count":179,"type":22},[53],"Parathyroid insufficiency is a common complication in thyroid surgery and occurs in 6.6 to 24%. Up to 4.4% suffer from permanent hypoparathyroidism requiring life-time substitution of calcium and vitamin D in order to maintain a normal calcium homeostasis. To prevent permanent postoperative parathyroid insufficiency after thyroidectomy, devascularized parathyroid glands are re-implanted intramuscularly by standard. To achieve graft function, meticulous preparation and division of parathyroid tissue is necessary as a prerequisite for tissue nutrition by diffusion until a recapillarization of the parathyroid fragments sets in. There are persistent controversies about the optimal technique for the autotransplantation. The injection of mashed parathyroid tissue into a muscle appears to be a fast, secure and easy tech-nique to provide a sufficient parathyroid hormone (PTH) production in cases of insufficient production of the glands left in-situ. The study is based on the hypothesis that intramuscular injection of mashed parathyroid tissue is a safe procedure that enables graft survival through diffusion and allows for the subsequent production of systemically measurable levels of parathyroid hormone (PTH). The intervention consists of injecting mashed parathyroid tissue into the brachioradialis muscle of the non-dominant arm. The primary objective is to evaluate this technique with respect to both local complications arising from the transplantation procedure and the functional performance of the graft over time. Outcome measures include the PTH gradient between the transplanted and non-transplanted arms, parathyroid hormone levels measured in the antecubital fossa of both arms, and calcium levels. The study population comprises 100 patients, and the trial is designed as a prospective multicentre study. The risk-benefit assessment indicates that the risks associated with participation-particularly local complications and potential graft malfunction-are expected to be low. In patients with familial or renal hyperparathyroidism, autotransplantation of small parathyroid fragments (approximately 1 mm in diameter) has been standard practice for decades. Additionally, the injection of mashed parathyroid tissue into the sternocleidomastoid muscle during surgery has been performed in many centers for years. However, that approach has the limitation that PTH originating from the graft cannot be reliably measured due to anatomical constraints.",[421],"Graft Function",[423,424,425],"graft function","parathyroid autotransplantation","postoperative hypothyroidism","2026-04-14",{"date":428,"type":33},"2026-04-17",{"date":430,"type":22},"2026-04-02",{"date":432,"type":22},"2027-04-01",{"name":39,"class":40},2,{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":51,"phases":444,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":453,"locationsCount":93},"100634194","measurement-of-ocular-blood-flow-and-retinal-oxygen-extraction-in-diabetic-patients-100634194","NCT07536516","Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients","DM OPF ROXY","Inclusion Criteria:\n\n* Men and women aged ≥ 18 years\n* Signed informed consent\n* Previously diagnosed diabetes mellitus\n* Normal ophthalmic findings except diabetic retinopathy, unless the investigator considers an abnormality to be clinically irrelevant\n* Planned initiation of therapy with GLP-1 receptor agonist (Semaglutide, Ozempic®; Liraglutide, Victoza®) or GIP\u002FGLP-1 receptor agonist (Tirzepatide, Mounjaro®) by a diabetes specialist\n\nExclusion Criteria:\n\n* Participation in a clinical trial in the 3 weeks preceding the screening visit\n* Symptoms of a clinically relevant illness in the 3 weeks before the first study day\n* Presence or history of a severe medical condition, except diabetes, as judged by the clinical investigator\n* Abuse of alcoholic beverages\n* Blood donation during the previous three weeks\n* Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator\n* Previous laser photocoagulation treatment in the study eye\n* Best corrected visual acuity \\\u003C 0.4 Snellen\n* Women of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception\n* Pregnancy, planned pregnancy or lactation",{"count":443,"type":22},20,[53],"The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP\u002FGLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP\u002FGLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.",[447],"Diabetes Mellitus","2026-04-10",{"date":428,"type":33},{"date":451,"type":33},"2025-11-28",{"date":146,"type":22},{"name":39,"class":40},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":462,"enrollmentInfo":463,"targetDuration":4,"studyType":51,"phases":465,"briefSummary":466,"conditions":467,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":93},"100555455","personalized-targeted-glioblastoma-therapies-by-ex-vivo-drug-screening-100555455","NCT06512311","Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening","Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial (ATTRACT)","ATTRACT","Inclusion Criteria:\n\n* Age 18-75\n* ECOG performance status 0-2\n* Newly diagnosed glioblastoma, IDH wildtype - according to the 2021 WHO classification of Tumors of the Central Nervous System\n* MGMT promotor unmethylated per local investigator\n* Tissue available for drug screening (successful PDC establishment from surgical material)\n* Scheduled for concomitant radio-chemotherapy with temozolomide\n* Written informed consent\n\nExclusion Criteria:\n\n* Current participation in another therapeutic clinical trial\n* Patients with a concurrent malignancy or malignancy within five years prior of study enrolment except for carcinoma in situ of the cervix, non-melanoma skin carcinoma or stage I uterine cancer within the last 3 years\n* Pregnant or lactating women\n* Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody \\[HBsAg\\] test and a positive anti-hepatitis B core antibody \\[HBcAb\\] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for anti-HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n* Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥350 cells\u002Fmm3 , no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended.\n* Any of the following co-morbidities:\n\n  * Pre-existing severe peripheral neuropathy (\\> CTCAE grade 2)\n  * Hepatic impairment (Bilirubin Level \\>1.5x-3x ULN)\n  * Kidney dysfunction (CrCl \\\u003C 59 mL\u002Fmin)\n  * Cardiac dysfunction with left ventricular ejection fraction \\\u003C60 %\n  * Any grade of interstitial lung disease\n  * Ongoing or previous history of rhabdomyolysis\n  * Acute pancreatitis\n  * QTcF ≥480 msec\n  * Diabetes mellitus with fasting glucose \\> 250mg\u002Fdl or 13.9 mmol\u002FL\n* Participants who are unable or unwilling to comply with the requirements of the protocol as assessed by the investigator.","75 Years",{"count":464,"type":22},240,[53],"Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.",[468],"Glioblastoma","2026-04-09",{"date":426,"type":33},{"date":472,"type":33},"2024-07-10",{"date":474,"type":22},"2031-12-31",{"name":39,"class":40},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":128,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":51,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":4},"100631112","is-cross-linked-hyaluronic-acid-a-biologic-alternative-for-alveolar-ridge-preservation-100631112","NCT07496437","Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation?","Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? A Single-blind, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n(1) Patients elder than 18 years in need of (2) maxillary non-molar tooth extraction, and (3) later rehabilitation with delayed implant installation.\n\nExclusion Criteria:\n\n(1) Patients with chronic diseases (e.g., uncontrolled diabetes mellitus, etc.) and\u002For (2) taking any medication, influencing hard or soft-tissue healing; (3) acute pain\u002Finfection or (4) presence of a fistula at the extraction site; (5) untreated periodontal disease; (6) \\>25% of the buccal bone plate missing after tooth extraction; (7) pregnancy; (8) history of hypersensitivity or allergy to xHyA or xenogenic bone substitute material; and (9) inability to attend the follow-up appointments.",{"count":370,"type":22},[53],"Even after atraumatic tooth removal and\u002For immediate implant placement, some reduction of the alveolar ridge dimension is expected. To counteract (or limit) this reduction, alveolar ridge preservation technique (ARP) was developed. However, standard ARP techniques, such as grafting with bone substitutes, have some concerns, such as a long healing time prior to implant installation, residual graft particles, and often the need of re-grafting at implant installation. To overcome some of these limitations biologics have been discussed as an alternative approach, such as cross-linked hyaluronic acid (xHyA). However, whether the use of biologics only can achieve comparable results to the standard techniques, has yet to be answered.\n\nThe aim of the present single-blind, randomized controlled clinical trial is to test non-inferiority in terms of mid-buccal alveolar ridge height resorption 4 months after ARP between 1) control\u002Fstandard treatment (i.e., grafting with bone substitutes and socket seal) and 2) test treatment (i.e., xHyA applied with a collagen sponge and socket seal) at maxillary non-molar teeth.\n\nForty-eight patients will be included and randomly assigned to one of the following 2 groups: 1) control group: standard ARP with deproteinized bovine bone material and covering of the socket with a free gingival graft (FGG) (n=24), 2) test group: application of xHyA soaked in a collagen sponge and covered by a FGG (n=24). The primary outcome parameter is the extent of mid-buccal alveolar ridge height resorption after 4 months, i.e., prior to implant installation, and the sample size calculation is based on a non-inferiority limit of 0.6 mm. The secondary outcome parameters are frequency of additional grafting at implant installation due to 1) a bony dehiscence or fenestration, 2) a thin buccal bone (\\\u003C 1.5 mm), or 3) contour improvement, cervical alveolar ridge width, alveolar ridge volume, histomorphometric assessment of alveolar ridge healing, feasibility of implant installation, aesthetic outcome parameters, patient reported outcome measures, changes in keratinized mucosa width, soft tissue healing, and assessment of postoperative complications. Patients will be followed up to 1 year after prosthetic restoration.",[487,488,489,490],"Alveolar Bone Resorption","Alveolar Ridge Enlargement","Tooth Extraction","Hyaluronic Acid","2026-03-22",{"date":493,"type":33},"2026-03-27",{"date":495,"type":22},"2026-04-01",{"date":497,"type":22},"2028-12-31",{"name":39,"class":40},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":128,"sex":18,"minAge":19,"maxAge":506,"enrollmentInfo":507,"targetDuration":4,"studyType":51,"phases":509,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":93},"100630644","phase-1-elucidating-the-relevance-of-the-psychedelic-experience-to-psilocybins-anti-anhedonic-effects-100630644","NCT07490353","Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial","Inclusion criteria:\n\nAll participants:\n\n* General health based on medical history, physical examination, blood draw, and electrocardiogram\n* Age 18 to 55 years\n* Right-handedness (due to potential lateralization effects of left-handed subjects)\n* Willingness and competence to sign the informed consent form\n* Normal BMI weight range (18.5-24.9)\n\nSpecific to healthy subjects:\n\n* Psychiatric health based on structured clinical interview for DSM-5 (SCID)\n* No concomitant medication\n\nSpecific to anhedonia patients:\n\n* Major depressive episode (first or recurrent) based on structured clinical interview for DSM-5 (SCID) and ICD-10\n* Fulfilling the ICD-10 diagnostic criterion of anhedonia\n* No concomitant medication, specifically also free of antidepressants or other psychopharmaceuticals (for at least 2 weeks, 5 weeks for fluoxetin)\n\nExclusion criteria:\n\nAll participants:\n\n* Current or history of neurological disease\n* Current medical illness requiring treatment\n* Pregnancy or current breastfeeding\n* Current or former substance dependency\n* Any contraindication for MRI\n* Failure to comply with the study protocol or to follow the instruction of the investigating team\n* Failure to confirm effective use of contraception in females at least 8 weeks before and after study participation each\n* First-degree relative with bipolar disorder or schizophrenia\n\nSpecific to healthy subjects:\n\n\\- Psychiatric diagnosis\n\nSpecific to anhedonia patients:\n\n\\- Psychiatric comorbidities excluding anxiety disorders and\u002For obsessive-compulsive disorders","55 Years",{"count":508,"type":22},85,[510],"PHASE1","The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are:\n\nPrimary Objectives\n\n1. Systematically categorize prohedonic effects (antianhedonic effects in patients with anhedonia in depression, increase in well-being in all participants).\n2. Test effects of psilocybin on brain network complexity measures during the hedonic experience using fMRI as a correlate for prohedonic (anti-anhedonic and well-being increasing) effects.\n3. Elucidate relevance of the psychedelic experience to these effects (clinical, behavioral, and imaging) in a pharmacological challenge using the 5-HT2A\u002FD2 antagonist risperidone and extensive characterization of the psychedelic experience. Secondary Objectives 4. Test the differential effects of the psychedelic experience on fMRI paradigms measuring symptoms shown to be altered in anhedonia, more specifically reward processing and sexual arousal. 5. Test the relevance of neuroplasticity (BDNF) and inflammatory parameters to anti-anhedonic, well-being promoting, and brain network dynamic complexity effects. 6. Test the effects of the psychedelic experience on BDNF and inflammatory parameters.\n\nResearchers will compare the effects of psilocybin in two separate sessions (one with psilocybin alone, one with co-administration of risperidone) in both patients with depression and anhedonia and healthy control participants.\n\nParticipants will:\n\n* Take 25 mg of psilocybin p.o. in two sessions, in one of the two sessions they will take 1 mg risperidone p.o. before ingestion of psilocybin, to block psilocybin's acute psychedelic effects.\n* Undergo 3 MRI sessions, one before the first psilocybin session ('baseline') and one session each on the day after each respective psilocybin session.\n* Perform a variety of tasks during each fMRI session to asses the treatment's effects on anhedonia.",[513,514],"Depression - Major Depressive Disorder","Anhedonia",[516,517,518,514,519,520,521,522,523,524,525,526],"Psilocybin","Psilocin","Psychedelic","Depression","MRI","fMRI","functional MRI","Pharmaco-Imaging","MDD","Serotonin","Risperidone","2026-03-19",{"date":529,"type":33},"2026-03-24",{"date":531,"type":33},"2025-11-01",{"date":533,"type":22},"2028-05-31",{"name":39,"class":40},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":128,"sex":18,"minAge":541,"maxAge":542,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":545,"conditions":546,"keywords":548,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":558,"locationsCount":93},"100629340","retinal-oxygen-metabolism-in-children-with-myopia-100629340","NCT07473401","Retinal Oxygen Metabolism in Children With Myopia","Inclusion criteria for children with myopia:\n\n* Children aged between 8 and 13 years (inclusive)\n* Signed informed consent of child and legal guardian\n* Normal ophthalmic findings except myopia\n* Cycloplegic spherical equivalent (SE) refraction ≤ -1.0dpt in both eyes\n* Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant\n\nInclusion criteria for healthy age- and sex-matched controls:\n\n* Children aged between 8 and 13 years (inclusive)\n* Signed informed consent of child and legal guardian\n* Normal ophthalmic findings\n* Cycloplegic spherical equivalent (SE) refraction between +0.5dpt and -0.5dpt\n* Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant\n\nExclusion Criteria:\n\n* Intake of stimulating beverages containing xanthine derivatives (tea, coffee, cola-like drinks) 12 hours before the study day\n* Previous eye abnormalities such as cataract, keratopathy, strabismus, amblyopia, ocular inflammation, trauma, or surgery\n* History of any disease or syndrome associated with severe myopia such as Marfan syndrome, Stickler syndrome, or retinopathy of prematurity\n* Non-axial cause of myopia\n* BCVA less than 20\u002F25\n* Intraocular pressure ≥ 21mmHg\n* Astigmatism ≤ -1.0dpt\n* Anisometropia ≥ 2dpt\n* Not able to read letters for visual acuity testing","8 Years","13 Years",{"count":544,"type":22},80,"The aim of the present study is to gain more information about retinal functional parameters in myopic children in Europe. For this purpose, a prospective case-control study in children aged between 8 and 13 years, as this is the usual age of myopia onset, will be conducted. Forty myopic children will be age- and sex-matched to non-myopic controls. Retinal oxygen extraction will be used as the main outcome parameter, as data from animal and human studies point towards an involvement of hypoxia in the disease process. In addition, other parameters probably linked to myopia will be investigated, such as retinal and choroidal blood flow as well as choroidal and retinal vessel density and anatomical structures such as choroidal and central retinal thickness. Also, questionnaires about lifestyle factors will be completed.",[547],"Myopia",[549,550,551],"Retinal oxygen extraction","blood flow","Vessel density","2026-03-10",{"date":554,"type":33},"2026-03-16",{"date":325,"type":22},{"date":557,"type":22},"2027-01-02",{"name":39,"class":40},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":567,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":93},"100627700","postoperative-outcomes-of-a-toric-addon-intraocular-lens-after-keratoplasty-and-cataract-surgery-100627700","NCT07452042","Postoperative Outcomes of a Toric AddOn Intraocular Lens After Keratoplasty and Cataract Surgery","Postoperative Outcomes of a Toric Add-On Intraocular Lens After Keratoplasty and Cataract Surgery","AddOn","Inclusion Criteria:\n\n* Gender: female, male, or diverse\n* Ophthalmological diagnosis: pseudophakic patients after keratoplasty\n* Age: 45 to 90 years\n* Complication-free cataract surgery using phacoemulsification and implantation of a posterior chamber lens.\n* Complication-free keratoplasty and regular postoperative corneal astigmatism \\> 1 diopter (D)\n* Pupil diameter in mydriasis \\> 5.5 mm\n\nExclusion Criteria:\n\n* Uncontrolled glaucoma\n* Proliferative diabetic retinopathy\n* Iris neovascularization\n* History of uveitis or iritis\n* Microphthalmus\n* Recurrent intraocular inflammation of unknown cause\n* Blindness in the other eye\n* Uncontrolled systemic or ocular disease\n* Pregnancy\n* Breastfeeding","45 Years","95 Years",{"count":570,"type":22},40,"The aim of this clinical study is to evaluate a toric add-on intraocular lens (IOL) for the correction of high astigmatism in patients who have undergone keratoplasty and cataract surgery. As this patient group often suffers from significant preoperative residual astigmatism, there is a relevant clinical need for effective and safe refractive treatment options. The implantation of a toric add-on IOL in the ciliary sulcus is intended to significantly reduce postoperative astigmatism and improve visual rehabilitation.\n\nThe study is designed as a prospective, monocentric clinical trial with a limited number of cases, as this is a rare condition with limited availability of suitable patients. It is being conducted in accordance with Section 3 of the Austrian Medical Devices Act (MPG 2021) and is investigating a CE-marked add-on intraocular lens implant used within its intended purpose. The postoperative refractive cylinder serves as the primary endpoint, as it reflects the actual effectiveness of astigmatism correction. The rotational stability of the add-on IOL, which significantly influences refractive precision, is recorded as a secondary endpoint.\n\nAll study participants will be examined pre- and postoperatively in accordance with applicable medical standards. The results should contribute to the optimization of refractive care after keratoplasty and assess the clinical applicability of toric AddOn IOLs in this specific indication.",[573,574,575],"Cataract and IOL Surgery","Keratoplasty","Toric Intraocular Lens Stability","2026-02-27",{"date":578,"type":33},"2026-03-05",{"date":580,"type":22},"2026-02",{"date":582,"type":22},"2029-02",{"name":39,"class":40},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":592,"targetDuration":4,"studyType":51,"phases":594,"briefSummary":595,"conditions":596,"keywords":598,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":93},"100625611","beflared-versus-vbx-for-fevar-100625611","NCT07424885","BeFlared Versus VBX for FEVAR","BeFlared FEVAR Stent Graft System© Versus GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis for Fenestrated Endovascular Aortic Repair - Randomized Controlled Unblinded Clinical Trial","BRAVE FEVAR","Inclusion Criteria:\n\n* written informed consent form signed by the patients before admission to the study;\n* age \\> 18 years;\n* power of judgement and understanding capability of person;\n* patients with juxtarenal, pararenal, paravisceral AAA, EL Type IA with a previous history of EVAR procedure or TAAA (extent I-IV in accordance with Crawford Classification) undergoing emergency\u002Felective treatment with FEVAR (custom-made or off-the-shelf endograft) at the Division of Vascular Surgery, Department of General Surgery, Medical University of Vienna.\n\nExclusion Criteria:\n\n* age \\\u003C 18 years;\n* all female patients with a pregnancy possibility (premenopausal)",{"count":593,"type":22},126,[53],"This randomized controlled unblinded trial aimes to compare BeFlared FEVAR Stent Graft System (BeFlared) with GORE® VIABAHN® VBX Balloon Expandable Endoprothesis (VBX) in patients undergoing endovascular aneurysm repair with fenestrated device (FEVAR).\n\nPrimary objectives:\n\n* compare cumulative device time between patients undergoing FEVAR with BeFlared and VBX brindging device;\n* compare target vessel (TV) instability at early, short-term and midterm follow-up in patients undergoing FEVAR with BeFlared and VBX brindging device.\n\nSecondary objectives:\n\n\\- compare intraoperative TV technical success in patients undergoing FEVAR with BeFlared and VBX bridging device.",[597],"Fenestrated Endovascular Aortic Repair",[599,600,601,602,603],"FEVAR","endovascular aortic repair","bridging stent graft","cannulation","target vessel instability","2026-02-24",{"date":576,"type":33},{"date":607,"type":33},"2026-02-19",{"date":609,"type":22},"2033-02",{"name":39,"class":40},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":619,"targetDuration":621,"studyType":23,"phases":4,"briefSummary":622,"conditions":623,"keywords":629,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":93},"100626499","drug-coated-balloon-primary-pci-in-st-segment-elevation-myocardial-infarction-100626499","NCT07436429","Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction","Drug Coated Balloon-Based Primary PCI in ST-segment Elevation Myocardial Infarction - The DCB-STEMI Multicenter Registry","DCB-STEMI","Inclusion Criteria:\n\n* All ST-elevation MI undergoing Primary PCI\n\nExclusion Criteria:\n\n* In-stent culprit lesion\n* Contraindications to antiplatelets\n* Stent implantation within 3 months before enrollment\n* Cardiac arrest, intubation, or cardiogenic shock\n* Life-expectancy less than one year",{"count":620,"type":22},300,"30 Days","Drug-eluting stent (DES)-based primary percutaneous intervention (pPCI) has been established as the standard of care for patients presenting with ST-segment elevation myocardial infarction (STEMI), having demonstrated superiority over thrombolysis, plain balloon angioplasty, and bare-metal stents. Recently, the use of drug-coated balloons (DCB) has expanded dramatically across a variety of anatomical and clinical settings, including de novo coronary lesions. A DCB-based pPCI strategy may simplify the procedure and mitigate the risks of inadequate stent sizing due to spasm or large thrombus burden, acute stent thrombosis, distal embolization, no reflow, and the relatively higher incidence of late stent-related adverse events compared with elective PCI. Despite these theoretical advantages, data on the safety and efficacy of DCB-based pPCI in STEMI remains limited.\n\nThe aim of this registry is to explore procedural and clinical outcomes of patients with STEMI treated with a DCB-based pPCI strategy.",[624,625,626,627,628],"Myocardial Infarction (MI)","ST-Elevation Myocardial Infarction","STEMI","STEMI (STE-ACS)","Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)",[630,631,632,633,634,635,636,637,638],"Drug-coated balloon","Primary percutaneous coronary intervention","De novo coronary lesion","Limus-coated balloon","Paclitaxel-coated balloon","Net adverse clinical events","Bleeding Academic Research Consortium bleeding","ST-segment elevation myocardial infarction","Drug-Eluting Balloon","2026-02-22",{"date":576,"type":33},{"date":642,"type":33},"2026-02-08",{"date":644,"type":22},"2026-07-01",{"name":39,"class":40},{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":654,"enrollmentInfo":655,"targetDuration":4,"studyType":51,"phases":657,"briefSummary":659,"conditions":660,"keywords":665,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":679,"leadSponsor":681,"locationsCount":682},"100160063","phase-2-antiangiogenic-therapy-for-children-with-recurrent-medulloblastoma-ependymoma-atrt-and-rare-cns-tumors-100160063","NCT01356290","Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent\u002FProgressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors","MEMMAT","Inclusion criteria for patients Stratum I: Relapsed or progressive medulloblastoma - completed Stratum II: Relapsed or progressive ependymoma (at least one site of untreated recurrent disease) Stratum III: Relapsed or progressive ATRT (at least one site of untreated recurrent disease) Stratum IV: Relapsed or progressive medulloblastoma (at least one site of untreated recurrent disease) Stratum V: Relapsed or progressive CNS tumor of various histologies or patients with exclusion criteria or adult patients (explorative) Histological confirmation at diagnosis or relapse Stratum IV: Confirmation of the medulloblastoma group by methylation; IDAT (Intensity Data; raw data of methylation array) Female or male, aged from 0 to \\\u003C20 years (at time of original diagnosis) Participants must have normal organ and bone marrow function (ALT \\\u003C5x institutional upper limit of normal, creatinine \\\u003C1.5x institutional upper limit of normal for age, WBC \\>1000\u002Fmm3, platelets \\> 20,000\u002Fmm3. Patients with values less than WBC 2000\u002Fmm3 or platelets 50,000\u002Fmm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol Karnofsky performance status ≥50. For infants and children less than 12 years of age, the Lansky play scale ≥50% will be used Written informed consent of patients and \u002F or legal guardian\n\nExclusion criteria for patients VP- or subdural peritoneal shunt dependency (can be included in Stratum V) Prior treatment with temozolomide\u002Firinotecan (can be included in Stratum V) Active infection, pregnancy or breast feeding Treatment for current relapse (surgery may be performed before MEMMAT treatment; patients with sites of disease not irradiated are still eligible for the protocol) Known hypersensitivity to any of the drugs in the protocol Active peptic ulcer Any significant cardiovascular disease not controlled by standard therapy e.g. systemic hypertension Anticipation of the need for major elective surgery during the course of the study treatment Any disease or condition that contraindicates the use of the study medication\u002Ftreatment or places the patient at an unacceptable risk of experiencing treatment-related complications Non-healing surgical wound A bone fracture that has not satisfactorily healed","19 Years",{"count":656,"type":22},232,[658],"PHASE2","Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities.\n\nAntiangiogenesis therapy has emerged as a new treatment option in solid malignancies. The frequent delivery of low doses of chemotherapy, referred to as metronomic or antiangiogenic chemotherapy, targets endothelial cells while reducing the toxicity associated with standard dose chemotherapy.\n\nThe aim of the study is to extend therapy options for children with recurrent or progressive medulloblastoma, ependymoma, ATRT, and CNS tumors of various histologies, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life.\n\nThe study will be conducted in independent strata. Stratum I (recurrent medulloblastoma): recently completed (Peyrl, 2023). Stratum II (recurrent ependymoma), III (recurrent ATRT) and V (recurrent CNS tumors of various histologies, patients with exclusion criteria and adult patients): The primary objective is to determine the response rate defined as the percentage of patients with complete response (CR), partial response (PR), stable disease (SD) or lack of recurrence at 6 months after start of antiangiogenic treatment. Stratum IV (recurrent medulloblastoma): To determine whether temozolomide, irinotecan, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt can increase the response rate after 6 months of treatment, compared with etoposid, cyclophosphamide, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt. Additionally, PFS, OS, toxicity, QoL, performance status, predictive and prognostic markers will be examined.\n\nIn stratum II and III, the study will follow an open label, single arm phase 2 design, and an open label randomized two-arm phase 2 design in Stratum IV, and the exploratory Stratum V.",[661,662,663,664],"Medulloblastoma Recurrent","Ependymoma Recurrent","ATRT Recurrent","Rare CNS Tumor Recurrent",[666,667,668,669,670,671,672,673,674],"Medulloblastoma","Ependymoma","ATRT","Relapse","Children","antiangiogenic","metronomic","intraventricular","Rare CNS tumor",{"date":676,"type":33},"2026-02-23",{"date":678,"type":33},"2014-04",{"date":680,"type":22},"2030-04",{"name":39,"class":40},22,""]